Open an account

Avenue Therapeutics

ATXI · OTC

$0.4042−$0.0258 (−6.00%)TodayMarket closed ·
No price history for this range.

About ATXI

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 1 full-time employees. The company went IPO on 2017-06-27. The firm is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees
1
Headquarters
Bay Harbor Islands, Florida
Listed
Jun 27, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
avenuetx.com

ATXI key statistics

Market cap
1.33M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.58K
Volume
104
Open price
$0.4042
High today
$0.4042
Low today
$0.4042
52 Week high
$0.9699
52 Week low
$0.15

Avenue Therapeutics (ATXI) at a glance

As of Oct 20, 2026, Avenue Therapeutics (ATXI) shares are priced at $0.4042, giving the company a market cap of 1.33M and a price-to-earnings ratio of 0.00.

Volume so far is 104 shares, below the average of 3.58K shares a day.

Over the past year Avenue Therapeutics has ranged from $0.15 to $0.9699, and now sits 31% of the way up that range.

Avenue Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q4 FY25 it reported -$0.22 per share against an estimate of $0.00.

ATXI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 140.7% on average.

  1. Q1 FY23: reported -$101.25 per share against an estimate of -$9.94
  2. Q2 FY23: reported -$39.00 per share against an estimate of -$22.18
  3. Q3 FY23: reported $4.50 per share against an estimate of -$19.89
  4. Q4 FY23: reported $4.50 per share against an estimate of -$7.65
  5. Q1 FY24: reported -$15.40 per share against an estimate of -$9.18
  6. Q2 FY24: reported -$6.43 per share against an estimate of -$1.07
  7. Q3 FY24: reported -$1.92 per share against an estimate of -$0.9588
  8. Q4 FY25: reported -$0.22 per share against an estimate of $0.00

ATXI news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Avenue Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.